



PROFILE

I am a biomedical scientist with a strong background in biochemistry, microbiology and immunology, and over 20 years of experience in infectious disease research, vaccine development, and translational science.

I completed my PhD by the University of East Anglia in 2000, followed by a post-doctoral period at the University of Leiden. In 2004, I joined Instituto de Medicina Molecular, Lisboa, Portugal (iMM), now the Gulbenkian Institute for Molecular Medicine (GIMM). I am a Group Leader of GIMM, and a Principal Investigator with Habilitation of the Faculdade de Medicina da Universidade de Lisboa. I am the author of over 160 scientific articles, an inventor of various patents, and I have earned several scientific and innovation prizes.

I have vast experience in leading international research teams and managing high-impact projects funded by leading international agencies and pharmaceutical partners. I am an experienced communicator with a strong public presence and commitment to science outreach, particularly in what relates to vaccine literacy.

DATE AND PLACE OF BIRTH

27 December 1970, Lisbon, Portugal

CURRENT ADDRESS

Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal

CONTACT

WEBSITE:

www.miguelprudencio.com

EMAIL ADDRESS:

miguel.prudencio@gimm.pt

mprudencio@medicina.ulisboa.pt

MIGUEL PRUDÊNCIO

P h D

EDUCATION

PhD

University of East Anglia, United Kingdom

1996-2000

BSc

Faculty of Sciences, University of Lisbon, Portugal

1989-1994

WORK EXPERIENCE

PRINCIPAL INVESTIGATOR

Faculty of Medicine, University of Lisbon (Portugal)

Dec. 2024 -

GROUP LEADER

Gulbenkian Institute for Molecular Medicine (Portugal)

Oct. 2024 -

INVITED ASSOCIATE PROFESSOR

Faculty of Medicine, University of Lisbon (Portugal)

Sep. 2019 – Dec. 2024

GROUP LEADER

Instituto de Medicina Molecular (Portugal)

Jun. 2013 – Sep. 2024

STAFF SCIENTIST

Instituto de Medicina Molecular (Portugal)

Jun. 2008 – May 2013

POST-DOCTORAL RESEARCHER

Instituto de Medicina Molecular (Portugal)

Aug. 2004 – May 2008

POST-DOCTORAL RESEARCHER

University of Leiden (The Netherlands)

Jul. 2000 – Jul. 2004

DISTINCTIONS AND AWARDS (SELECTION)

2023 - Universidade de Lisboa / CGD Award, Health Sciences

2021 – Habilitation, Faculty of Medicine, University of Lisbon

2020 – Pfizer / SCML Award for Clinical Research

2019 – Paul Harris Award, Rotary Foundation

2013 - National BES Innovation Contest, Grand Prize

2008 - Amélia da Silva de Mello Award for Health Sciences

2007 - CESPU International Research Award

OTHER TRAINING, COURSES AND WORKSHOPS (SELECTION)

- Course "The art of supervising students – Skills for effective and empowering supervision", hfp consulting, Lisbon, Portugal
- Course "Gender Diversity Awareness for Employers & Service Providers", Gender Identity Research & Education Society, Lisbon, Portugal
- Workshop "Communicating Your Research With Impact", Instituto de Medicina Molecular, Lisbon, Portugal
- GCE Xcelerator Pilot Workshop, Bill & Melinda Gates Foundation, Seattle, USA
- TRANSVAC's training course "Practical approaches to vaccine development", University of Lausanne, Switzerland
- "Effective Writing for Life Sciences Research and Grant Proposals Course", Instituto de Medicina Molecular, Lisbon, Portugal
- "Laboratory Management Course", EMBO, Ericeira, Portugal

SCIENTIFIC PUBLICATIONS (SELECTION FROM A TOTAL OF >160)

- D. Moita, M. Prudêncio (2024), "Whole-sporozoite malaria vaccines: where we are, where we are going", **EMBO Mol. Med.** 16, 2279-2289
- D. Moita, H. Nunes-Cabaço, C. Rôla, B. Franke-Fayard, C.J. Janse, A.M. Mendes, M. Prudêncio (2023), "Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines", **Vaccine**, 41, 7618-7625
- D. Moita, C. Rôla, H. Nunes-Cabaço, G. Nogueira, T.G. Maia, A.S. Othman, B. Franke-Fayard, C.J. Janse, A.M. Mendes, M. Prudêncio (2023), "The effect of dosage on the protective efficacy of whole-sporozoite formulations for immunization against malaria", **NPJ Vaccines**, 182, 1-12
- I.J. Reuling, A.M. Mendes, G.M. de Jong GM, A. Fabra-García, H. Nunes-Cabaço, G.J. van Gemert, W. Graumans, L.E. Coffeng, S.J. de Vlas, A.S.P. Yang, C.K. Lee, Y. Wu, A.J. Birkett, C.F. Ockenhouse, R. Koelewijn, J.J. van Hellemond, P.J.J. van Genderen, R.W. Sauerwein, M. Prudêncio (2020) "Safety and efficacy of a genetically modified rodent malaria parasite against Plasmodium falciparum malaria: an open-label randomized phase 1/2a trial", **Science Transl. Med.**, 12, eaay2578.
- A.M. Mendes, M. Machado, N. Gonçalves-Rosa, I.J. Reuling, L. Foquet, C. Marques, A.M. Salman, A.S.P. Yang, K.A. Moser, A. Dwivedi, B. Jiménez-Díaz, S. Viera, J.M. Santos, I. Albuquerque, S.N. Bhatia, J. Bial, I. Angulo-Barturen, J.C. Silva, G. Leroux-Roels, C.J. Janse, S.M. Khan, M.M. Moita, R.W. Sauerwein, M. Prudêncio (2018) "A Plasmodium berghei Sporozoite-Based Vaccination Platform Against Human Malaria", **NPJ Vaccines**, 3, 33

ORCID ID: <https://orcid.org/0000-0003-1746-6029>

Citations: >7600; h-index: 46; i10-index: 126

Complete List of Published Work: <https://miguelprudencio.com/research-outputs/publications/>

INVITED LECTURES (SELECTION)

- 6th ESCMID Conference on Vaccines (upcoming)
- European Respiratory Society Congress (Invited by Pfizer)
- Conference of the Portuguese Society for Pneumology (Invited by Pfizer)
- Public Health Congress (Invited by Pfizer)
- Gordon Research Conference
- British Society for Parasitology Meeting
- Malaria Vaccines for the World Meeting

ADVANCED TEACHING

PhD courses

- LisbonBioMed, PhD Programme, Instituto de Medicina Molecular, Lisbon, Portugal
- Advanced PhD Course, Molecular Biomarkers and Technologies, Fac. Pharmacy, Univ. Lisbon, Portugal
- Biology at the Host Microbe Interface PhD Program, Instituto de Gulbenkian de Ciência, Oeiras, Portugal
- PhD Program in Biological Systems, Functional & Integrative Genomics, Fac. Sciences, Univ. Lisbon, Portugal
- PhD Program in Basic and Applied Biology, Fac. Sciences, Univ. Porto, Portugal

MSc Courses

- MSc in Public Health and Tropical Medicine, Mozambique
- MSc in Molecular Biology and Genetics, Fac. Sciences Univ. Lisbon, Portugal
- MSc in Biochemistry and Biomedicine, Fac. Sciences Univ. Lisbon, Portugal
- MSc in Evolution and Developmental Biology, Fac. Sciences Univ. Lisbon, Portugal
- MSc in Molecular Genetics and Biomedicine, NOVA Science and Technology School, Portugal
- MSc in Biomedical Research, Fac. Medicine Univ. Lisbon, Portugal
- MSc in Clinical Microbiology and Emerging Infectious Diseases, Fac. Medicine Univ. Lisbon, Portugal

RESEARCH GRANTS AWARDED (SELECTION FROM THE LAST 5 YEARS)

- European Commission – Horizon Europe, 2024-2028 “OptiViVax - Optimising a High Efficacy Plasmodium vivax Malaria Vaccine”
- Merck KGaA, 2024-2028, Germany “Induction of Long-lasting Premunition against Malaria”
- “la Caixa” Banking Foundation Health Research, Spain, 2021-2025 “Whole-organism vaccines against P. falciparum and P. vivax malaria with enhanced efficacy and scope”
- Fundação para a Ciência e Tecnologia, Portugal, 2023-2024 “Ivermectin hybrids – insecticidal and multistage antiparasmodial drugs for malaria control”
- GSK Tres Cantos Open Lab Foundation, Spain, 2021-2023 “Generation, characterization and in vivo evaluation of a novel live malaria vaccine”
- Fundação para a Ciência e Tecnologia, Portugal, 2018-2022 “Enabling strategies for enhanced whole-sporozoite malaria vaccines”

SCIENTIFIC PEER REVISION AND EVALUATION

- Ad-hoc reviewer for >40 scientific journals published by major science publishers, including Nature Publishing Group, Cell Press, Elsevier, Wiley, EMBO Press, PLoS, Life Science Alliance and eLife Sciences Publications
- Scientific evaluation processes for public science funding agencies, including Fundação para a Ciência e Tecnologia (PT), European Research Council (EU), Medical Research Council (UK), Agence Nationale pour la Recherche (FR) and Multidisciplinary Center for Infectious Diseases (CH)
- Evaluation of applications to the Everis Foundation Innovation Award (ES), the Sociedade de Ciências Médicas de Lisboa/Pfizer Award (PT), the AstraZeneca Innovate Competition (PT), the Baillet Latour Medical Award (BE) and the Product Development Partnerships Fund (NL)

CONSULTANTSHIPS

- Technical Commission for Seasonal Vaccination, National Health Directorate, July 2024, Lisbon, Portugal
- Expert Consultation on Malaria Vaccine Research & Development, NIH/NIAID, June 2024, Rockville, MD, USA
- COVID-19 Therapies, Envision Pharma Group, September 2022, Leiden, The Netherlands
- COVID-19 Vaccination Policy Advisory Board: Booster Vaccines, Pfizer, May 2022, USA

TEAM LEADERSHIP

As Group Leader, I have consistently managed/supervised teams of 10-15 researchers, including a total of 13 post-doctoral researchers, 12 PhD students, 27 MSc students, and 15 research assistants, from 17 different countries of origin.

SCIENCE OUTREACH ACTIVITIES

- >500 Media Appearances (TV, Radio, Printed press) in relation to COVID-19 vaccination
- >20 Opinion Articles in reference newspapers (Público, Expresso) and Letters in scientific journals (*Nature Microbiology*, *Trends in Parasitology*, *Frontiers in Cellular and Infection Microbiology*)
- >30 participations in Webinars, Workshops and Public Lectures on vaccines, COVID-19 and malaria
- >10 Science Communication Events in pre-grad schools
- 4 Public Awareness Campaigns on vaccines and animal experimentation
- 2 TEDx talks on malaria vaccination
- E-learning FOCUS ON Course on viral respiratory infections (Invited by Pfizer)

OTHER PROFESSIONAL AND SCIENTIFIC ACTIVITIES

- 2020 – Setup of Instituto de Medicina Molecular's COVID-19 Diagnostics Task Force
- 2011 – FELASA B and C categories Researcher/Coordinator Accreditation for Animal experimentation
- 2010 - 2016 – Head of Instituto de Medicina Molecular's Biosafety Level 3 Facility.

PATENTS

- “Novel spiro-lactam compounds, process and uses thereof” (Inventor), WO/2018/207165. Granted USA 2023”
- “Infected Cell Cultures” (Inventor), European Patent Office EP 17 160 277.4. Filed 2017
- Genetically modified rodent Plasmodium parasites as platforms for a whole-organism malaria vaccine” (Inventor and co-Holder of Intellectual Property rights). Granted worldwide 2017